BioCentury
ARTICLE | Clinical News

ADU-214: Phase I started

January 18, 2016 8:00 AM UTC

Johnson & Johnson’s Janssen Biotech Inc. unit began a 2-part, open-label, U.S. Phase I trial to evaluate IV ADU-214 once every 21 days in 42 patients with advanced or metastatic NSCLC. The dose-escala...